Carvedilol Phosphate
Product Images NDC 60505-4716

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Carvedilol Phosphate (NDC 60505-4716). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Coreg-cr-chem-struc (Carvedilol Phosphate Extended Release Spl Graphic 01)

Chemical structure diagram of Carvedilol Phosphate, showing its molecular composition including phosphate and water of hydration components as indicated.*

FDA Label Image

Figure 1 Survival Analysis For Copernicus (intent To Treat) (Carvedilol Phosphate Extended Release Spl Graphic 02)

A line graph showing percentage mortality over a period of 21 months, comparing two groups labeled as Placebo and Carvedilol. The graph illustrates lower mortality percentages in the Carvedilol group compared to Placebo, with a noted statistical significance (P = 0.0014). The x-axis represents months, and the y-axis represents percentage mortality.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Phosphate Extended Release Spl Graphic 03)

A forest plot showing hazard ratios across various patient subgroups including men, women, different age groups, race, diabetic and ischemic status, heart rate categories, systolic blood pressure levels, and spironolactone use, with a reference line at hazard ratio 1.0 and confidence interval markers for each subgroup.*

FDA Label Image

Figure 3 (Carvedilol Phosphate Extended Release Spl Graphic 04)

A line graph showing cumulative percentage mortality over 24 months for two groups: placebo and Carvedilol. The x-axis represents months, and the y-axis shows percentage mortality. The graph indicates lower mortality in the Carvedilol group compared to placebo, with a p-value of 0.03 noted.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Phosphate Extended Release Spl Graphic 05)

A forest plot chart showing hazard ratios for various patient subgroups in a clinical study, comparing factors such as age, sex, timing post-myocardial infarction, beta-blocker use, Killip class, thrombolytic therapy, current/prior congestive heart failure, diuretic use, angina presence, hypertension, diabetes, heart rate, and systolic blood pressure. The plot displays point estimates and confidence intervals for hazard ratios with a reference line at 1.0.*

FDA Label Image

Figure 5. Changes From Baseline In Systolic Blood Pressure And Diastolic Blood Pressure Measured By 24-hour Abpm With Carvedilol Phosphate Extended-release Capsules (Carvedilol Phosphate Extended Release Spl Graphic 06)

Two line graphs showing the change in systolic and diastolic blood pressure (SBP and DBP) over 24 hours after a morning dose of Carvedilol Phosphate at three different dosages (20 mg, 40 mg, and 80 mg). The x-axis represents time in hours, and the y-axis shows blood pressure changes in mmHg. Each dosage is represented by differently styled lines.*

FDA Label Image

Carvedilol Phosphate Er 10mg Capsule 30 Count Label (Carvedilol Phosphate Extended Release Spl Graphic 07)

Carvedilol Phosphate extended-release capsules label with 10 mg strength. The package contains 30 capsules and directs once-a-day dosing. It is manufactured for Apotex Corp. and made in Canada. The label also includes storage instructions, a caution against accepting the product if the membrane seal is broken, and a note that the formulation differs from carvedilol tablets.*

FDA Label Image

Carvedilol Phosphate Er 20mg Capsule 30 Count Label (Carvedilol Phosphate Extended Release Spl Graphic 08)

Label for Carvedilol Phosphate extended-release capsules, 20 mg strength, with a 30-capsule count. The label indicates once-a-day dosing and is labeled for Apotex Corp. It includes storage and handling instructions, the NDC number 60505-3679-3, and manufacturing information from GlaxoSmithKline and Apotex Corp.*

FDA Label Image

Carvedilol Phosphate Er 40mg Capsule 30 Count Label (Carvedilol Phosphate Extended Release Spl Graphic 09)

Carvedilol Phosphate 40 mg extended-release capsules packaging label showing a quantity of 30 capsules. It includes dosing instructions stating once-a-day dosing and warnings about the capsule's membrane. The label lists Apotex Corp. as the manufacturer and provides storage information at 25°C.*

FDA Label Image

Carvedilol Phosphate Er 80mg Capsule 30 Count Label (Carvedilol Phosphate Extended Release Spl Graphic 10)

Carvedilol Phosphate 80 mg extended-release capsules, bottle label showing 30 capsules. The label states once-a-day dosing and emphasizes the capsule is extended-release. Manufactured for Apotex Corp., with manufacturing by GlaxoSmithKline. Includes storage instructions and warning about the membrane seal integrity.*

FDA Label Image

Carvedilol Phosphate Extended Release Spl Graphic 11

Carvedilol Phosphate extended-release capsules label, 10 mg strength, with once-a-day dosing. The package contains 30 capsules. Manufactured by GlaxoSmithKline and labeled for Apotex Corp. The label includes storage instructions, dosage warnings, and states the product is made in Canada.*

FDA Label Image

Carvedilol Phosphate Extended Release Spl Graphic 12

Carvedilol Phosphate extended-release capsules label showing 20 mg strength with once-a-day dosing. The label indicates the package contains 30 capsules, manufactured by GlaxoSmithKline and Apotex Corp. Storage instructions, warnings about the capsule membrane seal, and professional consultation advice in case of overdose are also present.*

FDA Label Image

Carvedilol Phosphate Extended Release Spl Graphic 13

Label for Carvedilol Phosphate extended-release capsules, 40 mg strength, with a quantity of 30 capsules. The label includes dosing instructions as once-a-day dosing, manufacturer details (GlaxoSmithKline RTP, NC), and shows it is manufactured for Apotex Corp. The label also includes storage instructions and warnings about the capsule's membrane seal integrity.*

FDA Label Image

Carvedilol Phosphate Extended Release Spl Graphic 14

Label for Carvedilol Phosphate extended-release capsules, 80 mg strength, with a 30 capsule count. The label includes dosage caution for once-a-day dosing, storage instructions, and manufacturer information listing Apotex Corp. and GlaxoSmithKline. It notes the product is made in Canada and highlights the NDC number 60505-4716-3.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.